Clinical trial registry record

Combretastatin A4 Phosphate in Patients With Neovascular Age-Related Macular Degeneration

A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 1, phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated December 6, 2017.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT01570790
Last registry update
December 6, 2017
Status
Completed
Phase
Phase 1, Phase 2
Sponsor
Johns Hopkins University
Enrollment
8
Countries
United States
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 1, Phase 2
Study design
NON RANDOMIZED · PARALLEL · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
8
Population
ALL · 50 Years
Duration
2003-05-01 to 2005-06-01
Intervention
Combretastatin A-4 phosphate; Combretastatin A-4 Phosphate
Comparator
Not reported
Outcomes measured
Safety and Tolerability — 12 weeks after the first infusion of the Study Drug; Dose Limiting Toxicities (DLT) — 12 weeks after the first infusion of the study drug; Maximum Tolerated Dose — 12 weeks after the first infusion of the study drug; Change in Best Corrected Visual Acuity — 4 and 12 weeks after first infusion of the study drug; Change in Central Retinal Thickness — 4 and 12 weeks following the first infusion of CA4P
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 1, Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Source terminology contains a controlled topic term. Title supplies ageing or longevity context.

Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.

vision aging
Read the original source →Export JSON